Keros Therapeutics has halted dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial ...

Recursion Pharmaceuticals is reshaping drug discovery with AI, strategic partnerships, and financial discipline for long-term ...

Johnson & Johnson and other pharma companies aim to change how the 340B Drug Pricing Program functions. Courts must rule if ...

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per share on the $0.10 par value common stock of the company.

Squibb announced that its Board of Directors has declared a quarterly dividend of 62c per share on the 10c par value common ...

Ciltacabtagene autoleucel achieved a 100% complete response rate in patients with high-risk smoldering multiple myeloma, as ...

By Nancy Lapid (Reuters) - Novel triple-drug therapies are showing promise for patients with various kinds of leukemia, ...

Savvy plaintiffs-side attorneys are leveraging this split to avoid bringing their FLSA collective action where the employer ...

Seattle-based marketing technology company Banzai International, which went public last year on the Nasdaq, announced an ...

Iambic Therapeutics, a clinical-stage biotechnology company developing novel therapeutics using its unique AI-driven ...

Based on the results of this study, current recommendations suggest that TNBC patients with tumors larger than 2 cm or with ...

By far, the largest acquisition of 2024 was Novo Holdings' yet-to-be-closed buyout of manufacturer Catalent at $16.5 billion.